[Hemodynamic effects on intravenous propafenone in hypertrophic myocardiopathy]. 1988

F Funck, and C Bourmayan, and P Cristofini, and M Desnos, and F Fernandez, and P Benoit, and A Wajman, and J Gay
Service de cardiologie, Hôpital Boucicaut, Paris.

None of the medical treatments of hypertrophic cardiomyopathy is perfect. In the present study conducted on 11 patients with hypertrophic cardiomyopathy in whom the usual treatments were either ineffective or badly tolerated, the haemodynamic effects of propafenone administered intravenously were investigated. The drug was injected centrally in doses of 2 mg/kg over 10 minutes, then by continuous intravenous infusion of 1.5 mg/min during 30 minutes. Various parameters were recorded before and after propafenone treatment by right and left cardiac catheterization. This anti-arrhythmic drug, which has beta-blocking and amiodarone-like properties, reduced left intraventricular obstruction but had no beneficial effect on diastolic function. The baseline and induced left intraventricular gradients were reduced from 30.4 to 17.7 mmHg and from 74 to 43 mmHg respectively. Diastolic function values showed a fall in dp/dt min from 1470 to 1307 mm/sec and an increase in T value from 0.066 to 0.084. The use of propafenone in hypertrophic cardiomyopathy must be accurately determined by long-term oral studies.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011405 Propafenone An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. Apo-Propafenone,Arythmol,Baxarytmon,Cuxafenon,Fenoprain,Jutanorm,Nistaken,Norfenon,Pintoform,Prolecofen,Propafenon AL,Propafenon Hexal,Propafenon Minden,Propafenone Hydrochloride,Propafenone Hydrochloride, (R)-Isomer,Propafenone Hydrochloride, (S)-Isomer,Propafenone, (+-)-Isomer,Propafenone, (R)-Isomer,Propafenone, (S)-Isomer,Propamerck,Rythmol,Rytmo-Puren,Rytmogenat,Rytmonorm,SA-79,Hydrochloride, Propafenone,SA 79,SA79
D002312 Cardiomyopathy, Hypertrophic A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY). Cardiomyopathy, Hypertrophic Obstructive,Cardiomyopathies, Hypertrophic,Cardiomyopathies, Hypertrophic Obstructive,Hypertrophic Cardiomyopathies,Hypertrophic Cardiomyopathy,Hypertrophic Obstructive Cardiomyopathies,Hypertrophic Obstructive Cardiomyopathy,Obstructive Cardiomyopathies, Hypertrophic,Obstructive Cardiomyopathy, Hypertrophic
D003971 Diastole Post-systolic relaxation of the HEART, especially the HEART VENTRICLES. Diastoles
D005260 Female Females
D006328 Cardiac Catheterization Procedures in which placement of CARDIAC CATHETERS is performed for therapeutic or diagnostic procedures. Catheterization, Cardiac,Catheterization, Heart,Heart Catheterization,Cardiac Catheterizations,Catheterizations, Cardiac,Catheterizations, Heart,Heart Catheterizations
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

F Funck, and C Bourmayan, and P Cristofini, and M Desnos, and F Fernandez, and P Benoit, and A Wajman, and J Gay
January 1968, Atti della Societa italiana di cardiologia,
F Funck, and C Bourmayan, and P Cristofini, and M Desnos, and F Fernandez, and P Benoit, and A Wajman, and J Gay
January 1988, Revista espanola de cardiologia,
F Funck, and C Bourmayan, and P Cristofini, and M Desnos, and F Fernandez, and P Benoit, and A Wajman, and J Gay
March 1971, Archives des maladies du coeur et des vaisseaux,
F Funck, and C Bourmayan, and P Cristofini, and M Desnos, and F Fernandez, and P Benoit, and A Wajman, and J Gay
May 1984, Journal of the American College of Cardiology,
F Funck, and C Bourmayan, and P Cristofini, and M Desnos, and F Fernandez, and P Benoit, and A Wajman, and J Gay
June 1984, Zhonghua nei ke za zhi,
F Funck, and C Bourmayan, and P Cristofini, and M Desnos, and F Fernandez, and P Benoit, and A Wajman, and J Gay
November 1996, Revista espanola de cardiologia,
F Funck, and C Bourmayan, and P Cristofini, and M Desnos, and F Fernandez, and P Benoit, and A Wajman, and J Gay
May 1990, Revista espanola de cardiologia,
F Funck, and C Bourmayan, and P Cristofini, and M Desnos, and F Fernandez, and P Benoit, and A Wajman, and J Gay
May 1984, Giornale italiano di cardiologia,
F Funck, and C Bourmayan, and P Cristofini, and M Desnos, and F Fernandez, and P Benoit, and A Wajman, and J Gay
June 1989, Zhonghua xin xue guan bing za zhi,
F Funck, and C Bourmayan, and P Cristofini, and M Desnos, and F Fernandez, and P Benoit, and A Wajman, and J Gay
March 1977, Minerva pediatrica,
Copied contents to your clipboard!